# Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)

> **NCT00461591** · PHASE3 · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 802 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Apaziquone
- **DRUG:** Placebo
- **PROCEDURE:** TURBT

## Key facts

- **NCT ID:** NCT00461591
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 802 (ACTUAL)
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00461591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00461591, "Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00461591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*